Evaluation of ICP-B794 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorBeijing InnoCare Pharma Tech Co., Ltd.
About this trial
An Open-Label, Multi-center, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ICP-B794 in Patients with Advanced Solid Tumors
Eligibility criteria
Qualifiers
Age ≥18 years and ≤75 years.
Histologically confirmed other locally advanced or metastatic solid tumors.
Life expectancy ≥3 months.
Adequate organs function within 7 days prior to the first dose of ICP-B794
Disqualifiers
Other active primary malignancies within 3 years prior to the first dose of investigational product.
Prior or current treatment with the similar drug or related treatment specified in the protocol.
Having a past medical history and unhealthy lifestyle history as specified in the protocol, or suffering from diseases as specified in the protocol.
Toxicities from prior anti-tumor therapy not recovered to ≤ Grade 1 (per CTCAE V5.0).
Trial design
Treatments tested in this trial
- ICP-B794
Treatment groups
410 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov